Crossmark

Screening out irrelevant cell-based models of disease

Crossref DOI link: https://doi.org/10.1038/nrd.2016.175

Published Online: 2016-09-12

Published Print: 2016-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Horvath, Peter

Aulner, Nathalie

Bickle, Marc

Davies, Anthony M.

Nery, Elaine Del

Ebner, Daniel

Montoya, Maria C.

Östling, Päivi

Pietiäinen, Vilja

Price, Leo S.

Shorte, Spencer L.

Turcatti, Gerardo

von Schantz, Carina

Carragher, Neil O.
License Information

Text and Data Mining valid from 2016-09-12
More Information

Article History

First Online: 12 September 2016

Competing interests

: L.P. is a founder and shareholder of OcellO B.V., a contract research organization that offers drug screening services. The content of the article is not influenced in any way by his involvement. P.H. is the founder and a shareholder of Single-cell technologies Inc., a biodata analysis company. The content of the article is not influenced in any way by his involvement. A.M.D. is the inventor of the suspension technology referred to in the article as Happy Cell. He is also a board member, director and shareholder of the company that distributes this technology. The content of the article is not influenced in any way by his involvement.